Narcolepsy acquisitions to boost Neuraxpharm’s CNS reach
Pharmaceutical company Neuraxpharm, focused on the treatment of central nervous system (CNS) disorders, has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US, excluding the… Read More